Nurix Therapeutics (NASDAQ:NRIX) announced that it achieved a $7 million research milestone under its collaboration with Pfizer (NYSE:PFE) to develop degrader antibody conjugates.
Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on small molecule therapies for cancer and immune disorders, reported its first-quarter 2026 financial results and provided a comprehensive update on its lead clinical programs on April 8, 2026.
Nurix Therapeutics (NASDAQ:NRIX) announced on June 8, 2026, that it has entered into a global licensing and collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg (NX-5948).
Nurix Therapeutics (NASDAQ:NRIX) released updated Phase 1a/b clinical data for its experimental leukemia drug, bexobrutideg, demonstrating sustained efficacy and high response rates across multiple lines of therapy for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
